Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver.


Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
06 Apr 2019
Historique:
received: 20 12 2018
accepted: 19 03 2019
entrez: 8 4 2019
pubmed: 8 4 2019
medline: 30 7 2019
Statut: epublish

Résumé

The homeostasis of lipid droplets (LDs) plays a crucial role in maintaining the physical metabolic processes in cells, and is regulated by many LD-associated proteins, including perilipin 5 (Plin5) in liver. As the putative sites of hepatitis C virus (HCV) virion assembly, LDs are vital to viral infection. In addition, the hepatic LD metabolism can be disturbed by non-structural HCV proteins, such as NS5A, but the details are still inexplicit. HCV NS5A was overexpressed in the livers and hepatocytes of wild-type and Plin5-null mice. BODIPY 493/503 and oil red O staining were used to detect the lipid content in mouse livers and hepatocytes. The levels of lipids, lipid peroxidation and inflammation biomarkers were further determined. Immunofluorescence assay and co-immunoprecipitation assay were performed to investigate the relationship of Plin5 and NS5A. One week after adenovirus injection, livers expressing NS5A showed more inflammatory cell aggregation and more severe hepatic injuries in Plin5-null mice than in control mice, which was consistent with the increased serum levels of IL-2 and TNF-α (P < 0.05) observed in Plin5-null mice. Moreover, Plin5 deficiency in the liver and hepatocytes aggravated the elevation of MDA and 4-HNE levels induced by NS5A expression (P < 0.01). The triglyceride (TG) content was increased approximately 25% by NS5A expression in the wild-type liver and hepatocytes but was unchanged in the Plin5-null liver and hepatocytes. More importantly, Plin5 deficiency in the liver and hepatocytes exacerbated the elevation of non-esterified fatty acids (NEFAs) stimulated by NS5A expression (P < 0.05 and 0.01 respectively). Using triacsin C to block acyl-CoA biosynthesis, we found that Plin5 deficiency aggravated the NS5A-induced lipolysis of TG. In contrast, Plin5 overexpression in HepG2 cells ameliorated the NS5A-induced lipolysis and lipotoxic injuries. Immunofluorescent staining demonstrated that NS5A expression stimulated the targeting of Plin5 to the surface of the LDs in hepatocytes without altering the protein levels of Plin5. By co-IP, we found that the N-terminal domain (aa 32-128) of Plin5 was pivotal for its binding with NS5A. Our data highlight a protective role of Plin5 against hepatic lipotoxic injuries induced by HCV NS5A, which is helpful for understanding the steatosis and injuries in liver during HCV infection.

Sections du résumé

BACKGROUND BACKGROUND
The homeostasis of lipid droplets (LDs) plays a crucial role in maintaining the physical metabolic processes in cells, and is regulated by many LD-associated proteins, including perilipin 5 (Plin5) in liver. As the putative sites of hepatitis C virus (HCV) virion assembly, LDs are vital to viral infection. In addition, the hepatic LD metabolism can be disturbed by non-structural HCV proteins, such as NS5A, but the details are still inexplicit.
METHODS METHODS
HCV NS5A was overexpressed in the livers and hepatocytes of wild-type and Plin5-null mice. BODIPY 493/503 and oil red O staining were used to detect the lipid content in mouse livers and hepatocytes. The levels of lipids, lipid peroxidation and inflammation biomarkers were further determined. Immunofluorescence assay and co-immunoprecipitation assay were performed to investigate the relationship of Plin5 and NS5A.
RESULTS RESULTS
One week after adenovirus injection, livers expressing NS5A showed more inflammatory cell aggregation and more severe hepatic injuries in Plin5-null mice than in control mice, which was consistent with the increased serum levels of IL-2 and TNF-α (P < 0.05) observed in Plin5-null mice. Moreover, Plin5 deficiency in the liver and hepatocytes aggravated the elevation of MDA and 4-HNE levels induced by NS5A expression (P < 0.01). The triglyceride (TG) content was increased approximately 25% by NS5A expression in the wild-type liver and hepatocytes but was unchanged in the Plin5-null liver and hepatocytes. More importantly, Plin5 deficiency in the liver and hepatocytes exacerbated the elevation of non-esterified fatty acids (NEFAs) stimulated by NS5A expression (P < 0.05 and 0.01 respectively). Using triacsin C to block acyl-CoA biosynthesis, we found that Plin5 deficiency aggravated the NS5A-induced lipolysis of TG. In contrast, Plin5 overexpression in HepG2 cells ameliorated the NS5A-induced lipolysis and lipotoxic injuries. Immunofluorescent staining demonstrated that NS5A expression stimulated the targeting of Plin5 to the surface of the LDs in hepatocytes without altering the protein levels of Plin5. By co-IP, we found that the N-terminal domain (aa 32-128) of Plin5 was pivotal for its binding with NS5A.
CONCLUSIONS CONCLUSIONS
Our data highlight a protective role of Plin5 against hepatic lipotoxic injuries induced by HCV NS5A, which is helpful for understanding the steatosis and injuries in liver during HCV infection.

Identifiants

pubmed: 30954078
doi: 10.1186/s12944-019-1022-7
pii: 10.1186/s12944-019-1022-7
pmc: PMC6451786
doi:

Substances chimiques

Acyl Coenzyme A 0
Perilipin-5 0
Triazenes 0
Triglycerides 0
Tumor Necrosis Factor-alpha 0
Viral Nonstructural Proteins 0
triacsin C 6M6D4602I5
NS-5 protein, hepatitis C virus EC 2.7.7.48

Types de publication

Journal Article

Langues

eng

Pagination

87

Subventions

Organisme : National Natural Science Foundation of China
ID : 81572471
Organisme : National Natural Science Foundation of China
ID : 31671416
Organisme : National Natural Science Foundation of China
ID : 81670792

Références

J Immunol Methods. 1988 Dec 9;115(2):195-8
pubmed: 3198923
Hepatology. 2000 Aug;32(2):405-12
pubmed: 10915750
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9599-604
pubmed: 11481452
J Virol. 2007 Aug;81(15):8122-30
pubmed: 17507484
PLoS Pathog. 2008 Mar 28;4(3):e1000035
pubmed: 18369481
J Virol. 2002 Jun;76(12):5974-84
pubmed: 12021330
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
FEBS Lett. 2009 Sep 3;583(17):2720-6
pubmed: 19631645
Biochim Biophys Acta. 2007 Feb;1771(2):210-27
pubmed: 17234449
Biochim Biophys Acta. 2012 Feb;1821(2):268-78
pubmed: 22063271
Trends Cell Biol. 2002 Nov;12(11):517-23
pubmed: 12446113
J Virol. 2003 May;77(9):5487-92
pubmed: 12692249
J Biol Chem. 2011 May 6;286(18):15707-15
pubmed: 21393244
Liver Int. 2009 Mar;29 Suppl 2:26-37
pubmed: 19187070
J Biol Chem. 2009 Nov 13;284(46):32116-25
pubmed: 19717842
Diabetes. 2006 Dec;55(12):3418-28
pubmed: 17130488
J Hepatol. 2013 Jun;58(6):1081-8
pubmed: 23354285
Hepatology. 2015 Mar;61(3):870-82
pubmed: 25179419
Biology (Basel). 2014 Dec 15;3(4):892-921
pubmed: 25517881
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Nov;1863(11):1423-1432
pubmed: 30591149
J Cell Biol. 2009 May 18;185(4):641-55
pubmed: 19451273
J Lipid Res. 2013 Apr;54(4):876-7
pubmed: 23417737
Sci Rep. 2016 Jun 10;6:27778
pubmed: 27282740
Eur J Cell Biol. 2013 Dec;92(12):374-82
pubmed: 24480419
Free Radic Res. 1998 Jun;28(6):659-71
pubmed: 9736317
J Lipid Res. 2007 Dec;48(12):2547-59
pubmed: 17878492
Nat Protoc. 2007;2(5):1236-47
pubmed: 17546019
Gut. 2006 Jan;55(1):123-30
pubmed: 16344578
Protoplasma. 2012 Jul;249(3):541-85
pubmed: 22002710
Annu Rev Biochem. 2012;81:687-714
pubmed: 22524315
J Biol Chem. 2000 Dec 8;275(49):38486-93
pubmed: 10948207
J Hepatol. 2007 Jun;46(6):999-1008
pubmed: 17188392
RNA Biol. 2011 Mar-Apr;8(2):258-69
pubmed: 21593584
Curr Protoc Cell Biol. 2016 Sep 01;72:3.15.1-3.15.13
pubmed: 27580706
J Biol Chem. 2013 Apr 5;288(14):9915-9923
pubmed: 23420847
J Biol Chem. 2005 Oct 28;280(43):36417-28
pubmed: 16126720
Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316-28
pubmed: 16054557
PLoS Pathog. 2013;9(4):e1003302
pubmed: 23593007

Auteurs

Jin Zhang (J)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Xing Gao (X)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Yuan Yuan (Y)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Chao Sun (C)

Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China.

Yuanlin Zhao (Y)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Liming Xiao (L)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Ying Yang (Y)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Yu Gu (Y)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Risheng Yang (R)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Peizhen Hu (P)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China.

Lijun Zhang (L)

Department of Clinical Laboratory Medicine, Tangdu Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, 710038, People's Republic of China.

Chao Wang (C)

Department of Pathology, The General Hospital of Western Theater Command, No. 270, Tianhui Road, Rongdu Avenue, Chengdu, 610083, People's Republic of China. wang_chao1987@126.com.

Jing Ye (J)

State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, No.169, Changle West Road, Xi'an, Shaanxi, 710032, People's Republic of China. yejing@fmmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH